From the Journals

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.

Share

  • 1

    Phase 2b trial evaluated PrimeC (celecoxib & ciprofloxacin) in ALS.

  • 2

    68 patients enrolled across 4 centers.

  • 3

    Safety comparable to placebo; no life-threatening events.

  • 4

    Slower decline in ALSFRS-R scores with PrimeC.

  • 5

    Early treatment linked to fewer ALS-related complications.

  • 6

    Biomarker changes associated with treatment.

  • 7

    Further investigation of PrimeC warranted based on results.

Original Source(s)

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

  • by Kathryn Wighton

  • March 17, 2026

Related Content

Aneurysmal Hemorrhage Triggers Systemic Effects

Researchers examine physiologic responses following rupture and link them to outcomes.

AF Stroke Prevention: Testing Ablation

In the randomized STABLED trial, adding catheter ablation to edoxaban did not reduce recurrent stroke or major cardiovascular outcomes.

Physician Burnout: How a Neurocritical Care/Stroke Physician Manages Work-Life Balance

May A. Kim-Tenser, MD, MHA, a neurointensivist/vascular neurologist shares her tips for combatting physician burnout.

  • by

  • March 16, 2026

  • 7 min